It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Index funds win long term largely because of lower costs and broad diversification. This brief introduces the cost advantage and payoff.
27,987 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Amazon and Shopify posted contrasting Q1 2026 results, underscoring a widening gap between a capital-heavy expansion ...
Whirlpool’s scale appliance demand is a telling gauge of how households spend on big-ticket upgrades. As the housing ...
Pi Network’s PI token slid about 10% in the last 24 hours, trading near $0.177 and hitting a two-week low as the proj...
Palantir faces a pivotal moment as 2025 results reinforce growth in AI-related revenue, yet lofty valuations keep inv...
Tapestry reports a record quarter as Coach powerfully taps Gen Z demand with a Goldilocks mix of luxury and accessibi...
3D Systems' Q1 2026 update sheds light on demand, margins, and cash flow across its printing systems, materials, and ...
A single memecoin bet grew into a multi-million payday after months of patience, underscoring how fast gains can mate...
President Trump is set to land in Beijing on May 14, asserting economic leverage as oil markets whirl. China’s reserv...
A high-profile insider move at Navan has investors weighing the stock. This guide breaks down what navan's chief acco...
The crypto world is buzzing about XRP and a potential 90% plunge. This article breaks down the history, risk factors,...
Investors are eyeing Cerebras Systems' chips faster claims against Nvidia's Blackwell models. This deep dive explains...